Revolution Medicines, Inc.
Common Stock · NASDAQ
Live TMS charts are coming soon.
Paper trading. Simulated, no real money.
No public theses on RVMD yet. When TMS traders open paper trades on it and make their thesis public, the long and short split, average conviction and hit rate show here.
Key stats load once market data is connected.
Revolution Medicines has reported updated data from a pancreatic cancer trial, according to a headline-only report. The details of the results are not available in this item.
Revolution Medicines reported updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel as a possible first-line treatment for metastatic pancreatic cancer, presented at the ENA Symposium in Barcelona.
No SEC financials for RVMD yet. Companies that file 10-K and 10-Q reports show revenue, earnings, cash flow and the balance sheet here.
Source: SEC filings (10-K, 10-Q).
Paper trading only. Nothing here is financial advice.